However, the addition of HER‐2 targeting therapy with trastuzumab to RT has been reported to have no significant effect on the local recurrence of HER‐2‐positive DCIS compared with RT alone.37 This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.